Skip to search formSkip to main contentSkip to account menu

aclidinium bromide

Known as: (3R)-3-((hydroxy(di-2-thienyl)acetyl)oxy)-1-(3-phenoxypropyl)-1-azoniabicyclo(2.2.2)octane bromide 
National Institutes of Health

Related topics

Related topics

5 relations
30 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza]60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaleraclidinium

Broader (1)

Tropanes

Narrower (1)

Tudorza

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
BACKGROUND Several dual bronchodilator combinations of long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist… 
Review
2014
Review
2014
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
PURPOSE The safety and efficacy of the second U.S.-approved long-acting inhaled anticholinergic for controlling bronchospasm in… 
2013
2013
One-Year Extension Study of ACCORD COPD I: Safety and Efficacy of Two Doses of Twice-daily Aclidinium Bromide in Patients with COPD
Abstract This was a 52-week, double-blind, extension study in which COPD patients previously treated with twice-daily (BID… 
2013
2013
Effects of aclidinium bromide in a cigarette smoke-exposed Guinea pig model of chronic obstructive pulmonary disease.
Long-acting muscarinic antagonists are widely used to treat chronic obstructive pulmonary disease (COPD). In addition to… 
2012
2012
Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition
Cigarette smoking contributes to lung remodelling in chronic obstructive pulmonary disease (COPD). As part of this remodelling… 
2012
2012
Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.
Aclidinium bromide is a novel, inhaled long-acting muscarinic antagonist with low systemic activity developed for the treatment… 
Review
2012
Review
2012
The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
Long-acting muscarinic antagonists (LAMAs) play a central role in the management of chronic obstructive pulmonary disease (COPD… 
2010
2010
Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.
AIM Aclidinium bromide is a muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD… 
Highly Cited
2009
Highly Cited
2009
Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
OBJECTIVE Aclidinium bromide is a novel antimuscarinic being developed for the treatment of chronic obstructive pulmonary disease… 
2009
2009
Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long‐Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants
Systemic exposure to anticholinergics used for chronic obstructive pulmonary disease (COPD) may lead to side effects. This study… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)